VP, Regulatory Affairs Strategy

Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. The 4DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4DMT in the future.
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery.
We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our Core Values drive the way we work together:
Dare to Cure
Break Boundaries
Beyond Yourself
Prepare & Execute Relentlessly
Join us in creating the future of genetic medicine.
GENERAL SUMMARY
4D Molecular Therapeutics (4DMT), located in Emeryville, CA, is a clinical-stage biotechnology company developing targeted genetic medicines using its proprietary AAV vector platform to treat serious unmet medical conditions. The Vice President, Regulatory Affairs Strategy, reporting to the Chief Regulatory and Quality Officer, is the company’s senior global regulatory strategist, accountable for designing and executing integrated US, EU, and international regulatory strategies that take 4DMT’s programs from IND through BLA/MAA and approval in major markets. The role sets regulatory direction on program and executive teams, leads the company’s most consequential interactions with FDA, EMA, and other health authorities, and leads the Regulatory Strategy team.
MAJOR DUTIES & RESPONSIBILITIES:
Develops and leads integrated global regulatory strategies (US, EU, UK, Japan, and other key markets) for 4DMT’s AAV gene therapy programs from IND through BLA/MAA and approval, aligned with corporate objectives and supported by risk assessments, probability-of-success analyses, and contingency plans.
Designs global development and submission sequencing, including CTA timing, BLA and MAA filing strategy, and use of FDA–EMA parallel scientific advice and other collaborative review mechanisms.
Builds regulatory evidence strategies for novel endpoints and trial designs, including surrogate or intermediate endpoints, external controls, and real-world evidence where appropriate, consistent with FDA and EMA expectations for gene therapy.
Serves as the regulatory lead on program and governance teams, translating regulatory requirements and precedent into development plans, target product profiles, and evidence-generation strategies.
Identifies and pursues expedited and special regulatory pathways in each region, including Fast Track, RMAT, Breakthrough Therapy, Priority Review, Accelerated Approval, the Commissioner’s National Priority Voucher program, PRIME, ILAP, SAKIGAKE, and orphan designations.
Plans and leads health authority interactions, including pre-IND, INTERACT, Type A/B/C, End-of-Phase 2, and pre-BLA meetings, EMA scientific advice, and PMDA consultations; directs briefing document strategy and preparation, prepares project teams, and serves as a primary company contact with FDA (CBER/OTP), EMA, and other agencies.
Leads regulatory strategy for, and oversees preparation of, major submissions, including INDs/CTAs and amendments, annual reports, DSURs, orphan and expedited program designation requests, pediatric plans (iPSP/PIP), and BLA/MAA, ensuring filings are accurate, high quality, and submitted on time.
Partners with clinical, nonclinical, CMC, biostatistics, safety/pharmacovigilance, and medical affairs to define submission content and to ensure development plans are acceptable to regulators.
In partnership with Regulatory CMC and Technical Operations, ensures regulatory strategy accounts for AAV-specific CMC topics, including potency assays, comparability, and manufacturing process changes.
Shapes target product profiles and target labeling strategy across regions in partnership with Medical Affairs and Commercial.
Provides regulatory strategy input to life cycle plans, including indication expansion, new populations, and post-approval commitments, in partnership with the Life Cycle Management team.
Partners with Regulatory Operations on submission planning and timelines for global filings.
Leads ex-US regulatory strategy and execution, adapting global plans to regional requirements (EMA/CAT, MHRA, PMDA, Health Canada, and others) and directing regional partners, CROs, and consultants.
Partners with Quality to support Pre-Approval Inspection and BIMO readiness, ensuring submitted content is consistent with actual processes and data.
Builds, leads, and develops the Regulatory Strategy team, including global regulatory leads, with responsibility for goal setting, budget, resourcing, and talent development.
Educates and trains company employees on regulatory requirements, processes, and health authority expectations.
Communicates regulatory strategies, risks, and probability of success to executive leadership, the Board as needed, cross-functional teams, and partners/collaborators; supports business development due diligence.
Maintains current knowledge of the global regulatory environment for gene therapy (including FDA CBER/OTP and EMA CAT/ATMP frameworks), regulatory precedent, and the competitive landscape, and communicates implications to program teams and senior management.
Shapes the external regulatory environment through engagement with industry groups, health authority workshops, and comments on draft guidance relevant to gene therapy.
Proactively identifies regulatory risks and proposes solutions that keep development plans on time while maintaining the highest standards of quality and compliance.
QUALIFICATIONS:
Education:
S. degree in the life sciences or a related discipline required
Advanced degree (Ph.D., J.D., PharmD, MBA, and/or M.S.) in the life sciences preferred
Experience:
S. with 18+ years of experience in the biopharmaceutical or biotechnology industries, or 14+ years with an M.S. degree, or 10+ years with a PhD or PharmD, with the majority in Regulatory Affairs.
8+ years of people management experience leading regulatory strategy teams. An equivalent mix of education and experience will be considered.
Experience within the viral vector gene therapy field required; AAV highly desirable. Direct experience with FDA CBER/OTP required.
Senior responsibility for at least one successful BLA or MAA (gene therapy, cell therapy, or biologic preferred), including direct ownership of global (US and EU) regulatory strategy through approval.
Demonstrated success negotiating novel development plans, endpoints, or expedited pathways with FDA CBER/OTP and EMA.
Track record leading EU regulatory strategy, including EMA scientific advice, PRIME or CAT interactions, and centralized MAA procedures; Japan or other international experience preferred.
Experience obtaining expedited program designations (e.g., RMAT, Breakthrough Therapy, Fast Track, PRIME, orphan).
Ophthalmology or pulmonology experience a plus.
Qualifications/Skills:
Expert knowledge of global regulations and guidance (FDA, EMA, ICH, MHRA, PMDA) and how they shape an integrated global regulatory strategy.
Proven ability to develop and execute global regulatory strategies that deliver approvals.
Strong track record of collaborative working relationships with FDA, EMA, and other health authorities that have led to successful outcomes for the business.
Ability to work within a team environment, report on projects and drive them to conclusions.
Self-starter who works with a sense of urgency and acts as a good team player working with other disciplines.
Adaptability, flexibility, independence and resourcefulness to roll-up-sleeves and multi-task to thrive in small company environment.
Ability to proactively identify challenges, possess strategic foresight and implement appropriate course of action
Must have thorough knowledge of drug de